SG11201403335WA - 1,5-naphthyridine derivatives and melk inhibitors containing the same - Google Patents

1,5-naphthyridine derivatives and melk inhibitors containing the same

Info

Publication number
SG11201403335WA
SG11201403335WA SG11201403335WA SG11201403335WA SG11201403335WA SG 11201403335W A SG11201403335W A SG 11201403335WA SG 11201403335W A SG11201403335W A SG 11201403335WA SG 11201403335W A SG11201403335W A SG 11201403335WA SG 11201403335W A SG11201403335W A SG 11201403335WA
Authority
SG
Singapore
Prior art keywords
same
inhibitors containing
naphthyridine derivatives
melk inhibitors
melk
Prior art date
Application number
SG11201403335WA
Other languages
English (en)
Inventor
Yo Matsuo
Shoji Hisada
Yusuke Nakamura
Feryan Ahmed
Joel R Walker
Raymond Huntley
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of SG11201403335WA publication Critical patent/SG11201403335WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11201403335WA 2012-01-19 2012-12-21 1,5-naphthyridine derivatives and melk inhibitors containing the same SG11201403335WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261588496P 2012-01-19 2012-01-19
PCT/US2012/071434 WO2013109388A2 (en) 2012-01-19 2012-12-21 1,5-naphthyridine derivatives and melk inhibitors containing the same

Publications (1)

Publication Number Publication Date
SG11201403335WA true SG11201403335WA (en) 2014-09-26

Family

ID=48799799

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403335WA SG11201403335WA (en) 2012-01-19 2012-12-21 1,5-naphthyridine derivatives and melk inhibitors containing the same

Country Status (16)

Country Link
US (2) US9067937B2 (zh)
EP (1) EP2753329B1 (zh)
JP (1) JP6159948B2 (zh)
KR (1) KR101920109B1 (zh)
CN (1) CN104968345B (zh)
AU (1) AU2012366148B2 (zh)
BR (1) BR112014014877B1 (zh)
CA (1) CA2857346C (zh)
DK (1) DK2753329T3 (zh)
ES (1) ES2642720T3 (zh)
IL (1) IL233529A (zh)
MX (1) MX366983B (zh)
RU (1) RU2645339C1 (zh)
SG (1) SG11201403335WA (zh)
TW (2) TWI623537B (zh)
WO (1) WO2013109388A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2582610C2 (ru) * 2010-07-30 2016-04-27 Онкотерапи Сайенс, Инк. Производные хинолина и содержащие их ингибиторы melk
US10254283B2 (en) 2013-11-12 2019-04-09 Dana-Farber Cancer Institute, Inc. Biomarker for MELK activity and methods of using same
WO2015073509A2 (en) * 2013-11-12 2015-05-21 Dana-Farber Cancer Institute, Inc. Biomarker for melk activity and methods of using same
WO2016141296A1 (en) 2015-03-04 2016-09-09 Dana-Farber Caner Institute, Inc. Tricyclic kinase inhibitors of melk and methods of use
US10729680B2 (en) * 2016-01-14 2020-08-04 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
BR112019003408A2 (pt) 2016-08-31 2019-06-25 Oncotherapy Science Inc anticorpo monoclonal contra a melk e utilização da mesma
NL2020004B1 (en) 2016-12-09 2018-07-02 Ary Flohil Jacob Treatment of diffuse intrinsic pontine glioma
US10981896B2 (en) 2017-03-02 2021-04-20 Board Of Regents, The University Of Texas System Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
CN111171020A (zh) * 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
FR2632639B1 (fr) * 1988-06-09 1990-10-05 Sanofi Sa Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent
US5240916A (en) * 1989-07-27 1993-08-31 Dowelanco Naphthyridine derivatives
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
ATE491044T1 (de) 2004-08-10 2010-12-15 Oncotherapy Science Inc Gene und polypeptide in verbindung mit brustkrebserkrankungen
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
EP1907581A2 (en) 2005-07-27 2008-04-09 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
AU2007238372A1 (en) * 2006-04-14 2007-10-25 Astrazeneca Ab 4-anilinoquinoline-3-carboxamides as CSF-1R kinase inhibitors
WO2008023841A1 (en) 2006-08-25 2008-02-28 Oncotherapy Science, Inc. Breast cancer-associated gene, melk, and its interactions with bcl-g
JP2010529031A (ja) * 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害剤としてのナフチリジン誘導体
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
EP2332939A1 (en) * 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
RU2582610C2 (ru) * 2010-07-30 2016-04-27 Онкотерапи Сайенс, Инк. Производные хинолина и содержащие их ингибиторы melk

Also Published As

Publication number Publication date
JP2015513313A (ja) 2015-05-07
WO2013109388A3 (en) 2015-02-05
TW201734015A (zh) 2017-10-01
JP6159948B2 (ja) 2017-07-12
KR20140115356A (ko) 2014-09-30
US9067937B2 (en) 2015-06-30
EP2753329A2 (en) 2014-07-16
MX366983B (es) 2019-08-01
TW201333005A (zh) 2013-08-16
US20150005302A1 (en) 2015-01-01
US20150328225A1 (en) 2015-11-19
WO2013109388A2 (en) 2013-07-25
BR112014014877B1 (pt) 2020-09-08
TWI623537B (zh) 2018-05-11
IL233529A (en) 2017-10-31
CN104968345A (zh) 2015-10-07
EP2753329A4 (en) 2015-11-25
BR112014014877A2 (pt) 2017-06-13
MX2014008780A (es) 2014-10-23
US9345709B2 (en) 2016-05-24
KR101920109B1 (ko) 2018-11-19
AU2012366148B2 (en) 2016-12-01
ES2642720T3 (es) 2017-11-17
IL233529A0 (en) 2014-08-31
CA2857346A1 (en) 2013-07-25
CN104968345B (zh) 2018-05-08
TWI623536B (zh) 2018-05-11
EP2753329B1 (en) 2017-08-09
WO2013109388A8 (en) 2013-09-26
DK2753329T3 (en) 2017-10-23
CA2857346C (en) 2019-06-04
AU2012366148A1 (en) 2014-06-05
RU2645339C1 (ru) 2018-02-21

Similar Documents

Publication Publication Date Title
HK1184331A1 (zh) 喹啉衍生物與含此之 抑制劑
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
IL233529A0 (en) 1, 5-naphthyridine derivatives and malac inhibitors containing them
HK1209277A1 (zh) -三嗪- -甲酰胺激酶抑制劑
HK1198646A1 (zh) 取代的咪唑並噠嗪類化合物及其用途
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
HK1216749A1 (zh) -萘啶衍生物
EP2837627A4 (en) AMIDOPYRIDINE DERIVATIVE AND USE THEREOF
HUE050104T2 (hu) 3,5N-trihidroxi-alkánamid és származékok: eljárás ennek elõállítására és ennek felhasználása
PT3024825T (pt) Imidazolecarboxamidas e seu uso como inibidores da faah
EP3048886A4 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
EP2737154A4 (en) DRILLING DEVICE AND APPLICATION METHOD THEREFOR
TWM432338U (en) M1010701_3919
AU2013901167A0 (en) Health Preservation
SG2013002043A (en) Tableware and support means for the same
TWM432299U (en) M1010701_3919
TWM432411U (en) M1010701_3919
TWM432309U (en) M1010701_3919
TWM432296U (en) M1010701_3919
TWM432298U (en) M1010701_3919
TWM432520U (en) M1010701_3919
TWM432312U (en) M1010701_3919
TWM432311U (en) M1010701_3919
TWM432356U (en) M1010701_3919